Impact of molecular residual disease post allografting in myelofibrosis patients
Standard
Impact of molecular residual disease post allografting in myelofibrosis patients. / Wolschke, C; Badbaran, A; Zabelina, T; Christopeit, M; Ayuketang, Francis Ayuk; Triviai, I; Zander, A; Alchalby, H; Bacher, U; Fehse, B; Kröger, Nicolaus-Martin.
In: BONE MARROW TRANSPL, Vol. 52, No. 11, 11.2017, p. 1526-1529.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of molecular residual disease post allografting in myelofibrosis patients
AU - Wolschke, C
AU - Badbaran, A
AU - Zabelina, T
AU - Christopeit, M
AU - Ayuketang, Francis Ayuk
AU - Triviai, I
AU - Zander, A
AU - Alchalby, H
AU - Bacher, U
AU - Fehse, B
AU - Kröger, Nicolaus-Martin
PY - 2017/11
Y1 - 2017/11
N2 - We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI: 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI: 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.Bone Marrow Transplantation advance online publication, 17 July 2017; doi:10.1038/bmt.2017.157.
AB - We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI): 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI: 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI: 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI: 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.Bone Marrow Transplantation advance online publication, 17 July 2017; doi:10.1038/bmt.2017.157.
KW - Journal Article
U2 - 10.1038/bmt.2017.157
DO - 10.1038/bmt.2017.157
M3 - SCORING: Journal article
C2 - 28714945
VL - 52
SP - 1526
EP - 1529
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 11
ER -
